Literature DB >> 19426244

Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study.

Jacob George1, Stuart Hannah, Chim C Lang.   

Abstract

Prescribing behavior may be linked to media influence rather than to scientific evidence. Recently, the oral diabetic drug class of thiazolidinedione has been under the spotlight because of concerns over their cardiovascular safety. We have therefore conducted an electronic questionnaire survey among prescribing physicians in Tayside, Scotland to evaluate the prescribing attitudes and knowledge of the available evidence regarding the cardiovascular safety of thiazolidinedione use. Nationally representative prescribing data thoughout Scotland and Tayside from the IMS Health RSA dataset were also examined. Prescriptions for rosiglitazone alone or in combination with metformin have steadily decreased since the publication of a meta-analysis suggesting harm from rosiglitazone. This was mirrored by a gradual increase in prescriptions of pioglitazone. However, when questioned, the majority of doctors rate the level of information received regarding drug safety information on thiazolidinediones to be low with 68% of respondents scoring 5 or less (scale 1-10) on the level of information received. The source of information regarding drug safety warning was highly varied ranging from journals (21%), scientific meetings (19%) and the news media (15%). The findings of this study clearly show a need to disseminate reliable drug safety information more effectively to prescribers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19426244     DOI: 10.1111/j.1755-5922.2009.00083.x

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  3 in total

1.  Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis.

Authors:  Christopher J Weatherburn; Bruce Guthrie; Tobias Dreischulte; Daniel R Morales
Journal:  Br J Clin Pharmacol       Date:  2019-12-16       Impact factor: 4.335

2.  State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning.

Authors:  Joseph S Ross; Cynthia Jackevicius; Harlan M Krumholz; Jennifer Ridgeway; Victor M Montori; G Caleb Alexander; Judy Zerzan; Jiaquan Fan; Nilay D Shah
Journal:  Health Aff (Millwood)       Date:  2012-01       Impact factor: 6.301

3.  Impact of rosiglitazone meta-analysis on use of glucose-lowering medications.

Authors:  Richard L Morrow; Greg Carney; James M Wright; Ken Bassett; Jenny Sutherland; Colin R Dormuth
Journal:  Open Med       Date:  2010-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.